Post on 08-Jun-2020
Warsaw, 12th November 2015
Results summary Q3 2015
Patient’s strategy principles
Agenda
page 2 | RESULTS SUMMARY| Q3 2015
• Summary Q3 2015
• Market and financial results
• Financial target execution for 2015
• Patient strategy principles
Results summary Q3 2015
105%
net result growth
in Q3 2015 (YoY)
PLN 79.2 million
net result excluding
non-recurring items
after three quarters
of 2015
Page 3 | RESULTS SUMMARY| Q3 2015
Growing pharmaceuticals wholesale market
5.95 5.89
6.51
5.996.24
6.47
7.12
6.40 6.44
12.4%2.6% 1.7% 4.4% 4.9%
9.9% 9,.% 6.9% 3.3%
3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q
Pharmaceuticals wholesale market in quarters and YoY dynamics
Q3 2013 – Q3 2015 (PLN billion)
Market growth
in Q1-Q3 2015
at the level of 6.5%
• Expected market dynamics slow-down in Q3
• Estimated further drop of market dynamics to the level of 2-3% in Q4
2013 2014 2015
page 4 | RESULTS SUMMARY| Q3 2015
NEUCA market position
Q1-Q3 2015:
28.9%
Q1-Q3 2014:
27.7%
87%
of pharmacies
in Poland
co-operate
with NEUCA Group
page 5 | RESULTS SUMMARY| Q3 2015
NEUCA programmes for pharmacies
Around
4000 participants
at the end of 2014
Around
4800 participants
at the end of Q3 2015
1/3
of pharmacies
in Poland participate
in the pharmaceutical
programmes
of NEUCA Group
Page 6 | RESULTS SUMMARY| Q3 2015
Our mission
We provide a better future to all
the independent
Pharmacies in Poland.
page 7 | RESULTS SUMMARY| Q3 2015
Client’s satisfaction* - NEUCA a quality leader
* Data from the Pharmaceutical Monitor published by IMS for Q3 2015 ccc
Complaint services
Telemarketing servicesTransport services Logistics services
4,52
4,244,2
NEUCA Pelion Farmacol
4,50
4,32
4,26
NEUCA Pelion Farmacol
4,624,54
4,38
NEUCA Pelion Farmacol
4,47
4,42
4,29
NEUCA Pelion Farmacol
4,18
4,07 4,07
NEUCA Pelion Farmacol
Regular offer Promotional offer
4,25
4,09 4,08
NEUCA Pelion Farmacol
page 8 | RESULTS SUMMARY| Q3 2015
Assortment widthSupply continuity
4,19 4,2
4,08
NEUCA Pelion Farmacol
4,314,28
4,19
NEUCA Pelion Farmacol
Clients satisfaction* - NEUCA a quality leader
Trade conditions Sense of security
4,41
4,35
4,29
NEUCA Pelion Farmacol
4,4
4,34
4,32
NEUCA Pelion Farmacol
* Data from the Pharmaceutical Monitor published by IMS for Q3 2015 page 9 | RESULTS SUMMARY| Q3 2015
FINANCIAL
RESULTS
Q3 2015
page 10 | RESULTS SUMMARY| Q3 2015
Revenues
1 737
4 789
1 648
5 231
3Q 2014 1-3Q 2014 3Q 2015 1-3Q 2015
+9%
• Market dynamics slow-down in Q3
• UOKiK decision execution effect considering ACP Bydgoszcz wholesaler sale
-5%
Sales revenues
[PLN million]
page 11 | RESULTS SUMMARY| Q3 2015
Operating profit
15.3
57.2
30.1
94.7
3Q 2014 1-3Q 2014 3Q 2015 1-3Q 2015
EBIT
[PLN million]
EBIT excluding non-recurring items
[PLN million]
+97%
+66%
17.8
62.2
30.1
95.7
3Q 2014 1-3Q 2014 3Q 2015 1-3Q 2015
+54%
+69%
• Maintaining sales and management costs at the level of Q3 2014
page 12 | RESULTS SUMMARY| Q3 2015
Net profit
• Neutral impact on the financial activity result
12.1
59.2
24.8
78.4
3Q 2014 1-3Q 2014 3Q 2015 1-3Q 2015
Net profit
[PLN million]Net profit excluding non-recurring items
[PLN million]
+105%
+32%
14.1
50.2
24.8
79.2
3Q 2014 1-3Q 2014 3Q 2015 1-3Q 2015
+75%
+58%
• Lack of non-recurring items in Q3
page 13 | RESULTS SUMMARY| Q3 2015
Sales and gross margin growth of private label products
Gross margin in private label products and number
if items
[PLN million, items]
6.9
13.7
18.9
8.2
12.4
204
325
436
2013 2014 2015
wynik brutto 1-3QRoczny wynik bruttoLiczba produktów na koniec 3Q
• Sales at the level of PLN 63.4 in Q1-Q3 2015 (growth by 54% YoY)
page 14 | RESULTS SUMMARY| Q3 2015
FINANCIAL TARGET
REALISATION
FOR 2015
page 15 | RESULTS SUMMARY| Q3 2015
Net result forecast excluding non-recurring items for 2015
79.2%
forecast
realisation
after Q1-Q3 2015
PLN 100 million
net profit
in 2015
page 16 | RESULTS SUMMARY| Q3 2015
PATIENT’S
STRATEGY
PRINCIPLES
page 17 | RESULTS SUMMARY| Q3 2015
Main market trends and mission
1. Increasing society welfare(income factor)
2. Ageing society(demografic factor)
3. Technology and medical knowledge development
(technologic factor)
Three factors stimulating growth of demand for
services on the healthcare and health protection
market
NEUCA Group’s mission in the
patient area
We facilitate access
to healthcare to
improve patients’
quality of life and
sense of security
page 18 | RESULTS SUMMARY| Q3 2015
Map of synergies
Pharmacy
Marketing
Advertising services
IT Services
Centre for Common Services
Logistics services
Packaging line
Private label
products
Pacjent
Telemarketing
Outpatient clinics
Telemedicine
Clinical trials
Patient
page 19 | RESULTS SUMMARY| Q3 2015
Values for patients and synergies
Creating a value for a patient through a number of synergies
we strengthen relation with our strategic client
– independent pharmacy.
1. We offer patients access
to high quality information
and knowledge(care in outpatient clinics)
2. We ensure access to
products and medical
services (private label products and clinical
trials)
3. We improve quality of life
and solve patients’ health
problems (telemedical
solutions)
1. Patients reactions
creation – improvement of
competitiveness and
profitability of pharmacies
2. Private labels products
and services portfolio
based on the knowledge of
patients
3. Promotion and sales
between the channels,
products and services
4. Co-operation with
producers
page 20 | RESULTS SUMMARY| Q3 2015
PHARMACY
Patient dedicated segments – outpatient clinics
Primary health care outpatient clinics in the Group
• 14 clinics in 6 regions
• Coverage 50 thousand patients with focus on primary healthcare
• Target investment budget PLN 30 million
• Mediporta – Electronic Medical Documentation for clinics
Market environment
• PLN 7.7 billion – estimated market value of primary healthcare
• Dispersed market – ca. 4% private care controlled by biggest players
• Over 52% of all medical advises administered by primary health care outpatient clinics
PLN 39 bn*National market
of private healthcare
PMR Estimates: 2015.
OUTPATIENTCLINICS
page 21 | RESULTS SUMMARY| Q3 2015
Patient dedicated segments – clinical trials
Clinical trials in the Group
• 3 complimentary companies: Clinport, Medica Pro Familia,
BioScience
• Focus on most profitable SMO model
• 7 centres in the country
• 120 ongoing clinical trials
Market environment
• 3 - 4 % average national growth of clinical trials
• 500 trials yearly commissioned by 50 entities
• 70% trials executed by foreign companies
PLN 1 billion*National market
of clinical trials
CLINICAL TRIALS
PMR Estimates: 2015. page 22 | RESULTS SUMMARY| Q3 2015
Patient dedicated segments – telemedicine
Telemedicine in Group
• Work on device to monitor diabetes - Diabdis
• Planned commercialisation of the device in 2016
• Co-operation with producers
Market environment
• 5 segments: telecare, telediagnostics, teleconsults, teleteaching, teletreatment
• Telecare and telediagnostics correspond to 60% of the market
• Lack of market regulations in Poland; development of telemedicine - one of the
strategy elements of Ministry of Health
PLN 27.9
billion* value of
telemedical
services
market
in Europe
Forecast for 2017, source KIGMED
TELEMEDICINE
page 23 | RESULTS SUMMARY| Q3 2015
Summary
Where we are Where we head to
• We develop a coherent
strategy around the access
to knowledge to products
and services for patients
• Synergies allow to develop a
sum of profits offered to
independent pharmacies to
increase their
competitiveness
• The takeover allows to reach
positive financial effects in
the margin level
• We reach significant financial
effect as contribution to net
profit visible in the three
year’s perspective
PharmacyPatient
Outpatient clinics
PLN 9.5 million*
revenues
14 premises,
50 thousand
patients
Telemedicine
Diabdis
– telemonitoring
for patients with
diabetes
Clinical trials
PLN 2.5 million*
revenues
7 premises,
120 trials
* Revenues for Q1- Q3 2015, since the take-over moment page 24 | RESULTS SUMMARY| Q3 2015
THANK YOU
FOR YOUR
ATTENTION!